Melanin and Dermal Uptake of Thirdhand Cigarette Smoke (THS05)

September 1, 2023 updated by: University of California, San Francisco
This is a pilot study of the effects of dermal melanin on dermal uptake and retention of nicotine. The initial hypothesis is that higher levels of dermal melanin will correlate with lower uptake and longer retention of nicotine in the skin and body.

Study Overview

Status

Not yet recruiting

Conditions

Detailed Description

This is an interventional pharmacokinetic study comparing the uptake and metabolism of nicotine from smoke-exposed clothing in people with low high levels of dermal melanin and people with high levels of dermal melanin. The study will measure nicotine and metabolites of nicotine in the blood during exposure and in urine for 10 days after exposure.

Study Type

Interventional

Enrollment (Estimated)

60

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

    • California
      • San Francisco, California, United States, 94110
        • Zuckerberg San Francisco General Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Adult nonsmoker
  • Aged 18-50
  • Skin reflectance scores below 150 or above 249 using the Mexameter 18 instrument
  • Healthy on the basis of medical history
  • Systolic blood pressure <150
  • Diastolic blood pressure <100
  • C-reactive protein <3.1 mg/ml
  • Liver function (AST and ALT) in normal ranges
  • kidney function (BUN) in normal ranges
  • LDL<131
  • Blood glucose <110
  • Not exposed to tobacco SHS.

Exclusion Criteria:

  • Dermal skin reflectance score between 150 and 249, as measured by the Mexameter 18 instrument.
  • Positive SARS-CoV-2 antibody test
  • Age 18 < or > 50
  • Physician diagnosis of asthma, heart disease, hypertension, thyroid disease, diabetes, renal or liver impairment or glaucoma.
  • Unstable psychiatric condition (such as current major depression, history of schizophrenia or bipolar disorder) or current use of more than two psychiatric medications
  • Systolic blood pressure greater than or equal to 150
  • Diastolic blood pressure greater than or equal to 100
  • Blood glucose greater than or equal to 110
  • LDL greater than or equal to130
  • Pregnancy or breastfeeding (by urine hCG and/or history)
  • Alcohol or illicit drug dependence within the past 5 years
  • BMI > 35 and < 18
  • Current illicit drug use (by history or urine test)
  • More than 1 pack year smoking history
  • Ever a daily marijuana smoker
  • Smoked anything within the last 3 months
  • Unable to hold allergy or other OTC medicines
  • Occupational exposure to smoke, dusts OR fumes
  • Concurrent participation in another clinical trial
  • Unable to communicate in English
  • No social security number

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Basic Science
  • Allocation: Non-Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Low melanin
Individuals with skin reflectance scores below 150 using the Mexameter 18 instrument.
Cotton clothing is exposed to smoke from Marlboro Red (hard pack) cigarettes at 1-1.2 mg/m3 repeatedly, until total exposure equals 3 grams total particulate material. When tested after exposure, the clothing typically contained 59.15 +/- 18 µg nicotine and 42 +/- 24 ng NNK per gram. The mass of the clothing varies by size, but the average combination of pants and shirt contains 32 mgs nicotine and 23 µg NNK.
Experimental: High melanin
Individuals with skin reflectance scores above 249 using the Mexameter 18 instrument
Cotton clothing is exposed to smoke from Marlboro Red (hard pack) cigarettes at 1-1.2 mg/m3 repeatedly, until total exposure equals 3 grams total particulate material. When tested after exposure, the clothing typically contained 59.15 +/- 18 µg nicotine and 42 +/- 24 ng NNK per gram. The mass of the clothing varies by size, but the average combination of pants and shirt contains 32 mgs nicotine and 23 µg NNK.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Total combined urinary concentrations of the nicotine metabolites cotinine and 3-hydroxycotinine
Time Frame: First void, collected for 10 days
The study will measure urinary metabolites of nicotine in the first void of the day for 10 days after exposure and sum the total mass of metabolites.
First void, collected for 10 days
Change in blood concentrations of nicotine
Time Frame: Baseline and 3 hours
The study will measure concentration of nicotine in the blood before and after the dermal exposure to nicotine.
Baseline and 3 hours

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Urinary concentration of the NNK metabolite NNAL
Time Frame: First void, collected for 10 days
The study will measure urinary metabolites of NNK in the first void of the day for 10 days after exposure and sum the total mass of metabolites.
First void, collected for 10 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Suzaynn F Schick, PhD, University of California, San Francisco

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

September 1, 2023

Primary Completion (Estimated)

November 1, 2025

Study Completion (Estimated)

November 1, 2025

Study Registration Dates

First Submitted

August 25, 2023

First Submitted That Met QC Criteria

August 25, 2023

First Posted (Actual)

August 31, 2023

Study Record Updates

Last Update Posted (Estimated)

September 6, 2023

Last Update Submitted That Met QC Criteria

September 1, 2023

Last Verified

September 1, 2023

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Healthy

3
Subscribe